Skip to main content
. Author manuscript; available in PMC: 2013 Nov 1.
Published in final edited form as: Mol Cancer Ther. 2013 Feb 20;12(5):819–828. doi: 10.1158/1535-7163.MCT-12-0905

Figure 2.

Figure 2

GDC-0941 inhibits PI3-K signaling in drug sensitive U87 tumors. Western blot data for expression of pAKT, tAKT, pGSK-3β &tGSK-3β in U87 (A) and HCT116 (B) tumors, with densitometric analysis in C and D respectively (Average ± SEM, *p<0.01). Data are representative of 4 independent mice dosed with vehicle or 50 mg/kg GDC-0941 twice daily for 8 days and were normalized to β-actin.